Drug
Nalbuphine ER (Haduvio™)
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system.
Study Purpose
This is a multi-center randomized, double-blind, placebo-controlled, parallel, 4-arm study of nalbuphine ER (NAL ER).